Name | tert-butyl (3E)-3-[(6-morpholin-4-ylpyridazin-3-yl)hydrazinylidene]butanoate |
---|---|
Synonyms | GYKI-11679 |
Description | GYKI-11679 is a new antihypertensive agent. |
---|---|
Related Catalog | |
In Vivo | GYKI-11679 is a new antihypertensive agent. Results show a sharp (61%) reduction in the hypothalamic Noradrenaline (NA) level 2 h after the administration of 10 mg/kg of GYKI-11679, and this effect lasts for 4 to 6 h. It is demonstrated that GYKI-11679 exerts a greater NA lowering effect in the hypothalamus than in the periphery. GYKI-11679 does not influence the hypothalamic monoamine oxidase (MAO)-activity following prolonged treatment[1]. |
Animal Admin | Rats are used and treated with GYKI-11679 (0.5 mL of 1% Tween 80 suspension) at various dosages. They are killed at the specified times by decapitation; the heart is immediately removed, cut open, and rinsed in an isotonic saline solution. The brain is placed on ice and the hypothalamus is dissected. The tissues are weighed, homogenized in 5% trichloroacetic acid (TCA) containing 0.2% EDTA and ascorbic acid, and centrifuged for 1 h at 5000×g. The supernatant is processed on alumina and noradrenaline in the eluate is determined spectrofluorimetrically[1]. |
References |
Density | 1.22g/cm3 |
---|---|
Boiling Point | 528.421ºC at 760 mmHg |
Molecular Formula | C16H25N5O3 |
Molecular Weight | 335.40100 |
Flash Point | 273.38ºC |
Exact Mass | 335.19600 |
PSA | 92.17000 |
LogP | 1.31970 |
Index of Refraction | 1.574 |
~53% 69579-13-1 |
Literature: Szilagyi; Kasztreiner; Matyus; et al. European Journal of Medicinal Chemistry, 1984 , vol. 19, # 2 p. 111 - 117 |